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Aichi Cohort Study of Prognosis in Patients Newly Initiated Into Dialysis (AICOPP)Abstract
Background: In patients on maintenance dialysis, increased serum calcium levels are known to be associated with
a poor prognosis. However, it is not known whether serum calcium levels at dialysis initiation have an impact on
subsequent prognosis.
Methods: The subjects were patients who were newly initiated dialysis at the 17 Aichi Cohort Study of Prognosis in
Patients Newly Initiated into Dialysis (AICOPP) group centers. The study included 1524 patients who were at least
20 years old, had CKD, and provided written consent. We excluded one patient whose serum adjusted calcium was
not assessed and six patients whose outcomes were unknown. Thus, we enrolled 1517 subjects into the study. The
patients were divided into the following five groups: (1) G1 with a serum adjusted calcium level <7.0 mg/dL, (2) G2
with 7.0 to <8.0 mg/dL, (3) G3 with 8.0 to <9.0 mg/dL, (4) G4 with 9.0 to <10.0 mg/dL, and (5) G5 with ≥10.0 mg/dL.
The study outcomes included: (1) comparisons of all-cause mortality rates in the five groups; (2) extraction of factors
influencing all-cause mortality.
Results: There were 268 deaths during the follow-up period (G1, 9 cases; G2, 30 cases; G3, 91 cases; G4, 110 cases; G5, 28
cases). Significant differences were observed between the five groups’ cumulative survival rates (Logrank test p= 0.005) by
using Kaplan-Meier method. There were significant differences in the incidence of either aortic or cardiac valve calcification
among the five groups (aortic calcification: p= 0.006, cardiac valve calcification: p = 0.008). Moreover, lower Barthel Index,
which evaluated activities of daily living, were associated with higher serum adjusted calcium levels (p < 0.001). Multivariate
Cox proportional hazard analysis using the stepwise method indicated that increasing serum adjusted calcium was
associated with all-cause mortality (every 1 mg/dL increase, HR = 1.267, 95% CI = 1.092 − 1.470, p= 0.002). In addition, high
mortality was associated with advanced age, male gender, low systolic blood pressure, history of cardiovascular disease,
and no prior use of calcium carbonate.
Conclusions: Serum adjusted calcium levels at dialysis initiation were demonstrated to be associated with all-cause
mortality after dialysis initiation.
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In patients newly starting dialysis, advanced age and
concurrent cardiovascular diseases (CVDs) are major
problems which are strongly associated with survival
prognosis. The concept of chronic kidney disease-
mineral and bone disorders (CKD-MBD) focuses on
survival prognosis rather than bone lesions, and
management of serum phosphorus and calcium
levels is considered to be especially important [1]. In
patients on dialysis, serum phosphorus levels have
been shown to have a U-shaped association with
mortality [2–7]. As for serum calcium levels,
although it is not clear whether low levels are detri-
mental, high levels are known to be associated with
a poor prognosis [3, 4, 8]. Given these background
conditions, each guideline provides target values for
serum phosphorus and calcium levels when
managing patients on dialysis [1, 9].
Increased serum calcium levels reportedly cause vas-
cular calcification and carry a risk of CVD [10–12].
However, serum calcium levels often tend to decrease
during the predialysis stage of CKD including the period
immediately before dialysis initiation [13]. Although
secondary hyperparathyroidism has already manifested
in this stage, it rarely progresses to nodular hyperplasia
and is unlikely to cause hypercalcemia. Doi et al.
documented a serum calcium level >8.5 mg/dL at dialy-
sis initiation to be associated with outcomes at one year
after dialysis initiation [14], but only a few other reports
have described similar findings. Whether the association
observed in patients on maintenance dialysis between
serum calcium levels and survival prognosis is also
present in patients starting dialysis merits investigation.
Thus, the present study aimed to elucidate the associ-
ation between serum calcium levels at dialysis initiation
and subsequent prognosis.Methods
Subjects
The subjects were patients who were newly initiated
dialysis at the 17 Aichi Cohort Study of Prognosis in
Patients Newly Initiated into Dialysis (AICOPP) group
centers from October 2011 to September 2013 [15].
Patients who were withdrawn from dialysis while
hospitalized, died while hospitalized, or did not agree
to be registered were excluded. The study included
1524 patients who were at least 20 years old, had
CKD, and provided written consent. We excluded one
patient whose serum adjusted calcium was not
assessed and six patients whose outcomes were
unknown, as determined by a survey conducted at
the end of March 2015. Thus, we enrolled 1517 sub-
jects into the study.Patient characteristics and data when dialysis was
initiated (baseline)
Body mass index (BMI) was measured at the first
dialysis session. Diabetes was defined as a fasting
blood glucose ≥126 mg/dL, casual blood glucose
≥200 mg/dL, HbA1c (NGSP) ≥6.5%, use of insulin, or
use of oral hypoglycemic agents. History of cardiovas-
cular disease (CVD) was defined as a history of heart
failure requiring hospitalization, coronary artery
disease requiring coronary artery intervention or heart
bypass surgery, stroke, aortic disease requiring
surgery, or peripheral artery disease requiring
hospitalization. The period of nephrology care was
established, based on patients’ medical records, as the
period from referral to the nephrologist until the
initiation of dialysis. Medication use referred to the
drugs taken at dialysis initiation. Blood tests were
performed on samples taken before the first dialysis
session. Blood pressure was measured before the first
dialysis session.
Group assignment according to serum adjusted calcium
levels
The serum calcium levels at dialysis initiation of patients
with a serum albumin level <4.0 g/dL were adjusted
employing the Payne formula. According to adjusted
serum calcium levels, the patients were divided into the
following 5 groups: (1) G1 with a serum adjusted
calcium level <7.0 mg/dL, (2) G2 with 7.0 to <8.0 mg/dL,
(3) G3 with 8.0 to <9.0 mg/dL, (4) G4 with 9.0 to
<10.0 mg/dL, and (5) G5 with ≥10.0 mg/dL.
Assessment of aortic and cardiac valve calcification
Aortic calcification was assessed according to the
presence or absence of aortic arch calcification on plain
frontal chest radiographs taken immediately before
dialysis initiation. Cardiac valve calcification was
assessed according to the presence or absence of a calci-
fied aortic or mitral valve determined by B-mode echo-
cardiography during the 1-month periods before and
after dialysis initiation.
Assessment of activities of daily living with the Barthel
index
The BI is composed of 10 items: (1) eating, (2) transfer-
ring between the bed and wheelchair, (3) grooming, (4)
using the toilet, (5) bathing, (6) walking on a flat surface,
(7) climbing and descending stairs, (8) dressing, (9) con-
trolling bowel movements, and (10) controlling urination.
Each item is evaluated on a 2-point (0 and 5) to 4-point
(0, 5, 10, and 15) scale, and the total score (0−100 in incre-
ments of 5) is used for assessment [16]. In the present
study, experienced nurses assessed the patients to
determine the BI on discharge for dialysis initiation.
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Survival prognosis as of March 31, 2015 was determined
by surveying medical records. For patients who were
transferred to other institutions, information was ob-
tained by mailing out survey forms.
Outcomes
The study outcomes included (1) comparisons of all-
cause mortality rates in the five groups as categorized by
serum adjusted calcium level; (2) extraction of factors,
which included serum adjusted calcium, influencing all-
cause mortality.
Statistical processing
The easy R (EZR) was used for statistical processing







Age (years old) 67.5 + 13.1 60.4 + 14.0 63.8 +
Female gendera 491 (32.4) 43 (37.7) 61 (2
BMI (kg/m2) 23.5 + 4.4 23.5 + 4.2 24.7 +
SBP (mmHg) 151 + 26 154 + 24 154 +
DBP (mmHg) 77 + 15 82 + 14 80 + 1
Diabetes Mellitusa 774 (51.0) 39 (34.2) 125 (
Cancer-bearing 93 (6.1) 5 (4.4) 16 (6.
History of CVD 681 (44.9) 29 (25.4) 98 (40
Barthel index scoreb 100 (90-100) 100 (100-100) 100 (
Use of ACEIs or ARBsa 913 (60.2) 64 (56.1) 146 (
Use of beta blockersa 525 (34.6) 32 (28.1) 89 (3
Use of VDRAsa 412 (27.2) 30 (26.3) 58 (2
Use of calcium carbonatea 531 (35.0) 45 (39.5) 91 (3
Use of thiazidea 347 (22.9) 18 (15.8) 62 (2
Use of ESAsa 1303 (85.9) 92 (80.7) 203 (
Hemoglobin (g/dL) 9.4 + 1.6 8.8 + 1.8 9.4 +
Serum albumin (g/dL) 3.20 + 0.60 3.44 + 0.45 3.25 +
BUN (mg/dL) 91.8 + 30.4 105.3 + 34.3 96.9 +
eGFR (ml/min/1.73 m2) 5.44 + 2.22 4.21 + 1.36 4.92 +
Serum creatinine (mg/dL) 8.98 + 3.22 11.53 + 4.52 9.97 +
Serum adjusted calcium (mg/dL) 8.62 + 1.06 6.37 + 0.52 7.50 +
Serum phosphorus (mg/dL) 6.36 + 1.88 7.89 + 2.24 7.01 +
Alkaline phosphatase (IU/L) 265 + 173 291 + 137 272 +
PTH (pg/mL)b 292 (186-432) 440 (329-625) 375 (
CRP (mg/dl)b 0.30 (0.10-1.34) 0.31 (0.09-1.36) 0.32 (
Duration of NCb 588 (160-1307) 576 (77-1226) 579 (
Mean ± SD, avalue (%), bmedian (inter-quartile range)
G1 with a serum adjusted calcium level <7.0 mg/dL, G2 with 7.0 to <8.0 mg/dL, G3
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, CTR
enzyme inhibitor, ARB angiotensin-1 receptor blocker, VDRA vitamin D receptor acti
estimated glomerular filtration rate, PTH parathyroid hormone, CRP C reactive protebetween the five groups of patients were performed
using the analysis of variance (ANOVA) for continuous
variables and chi-square test for nominal variables. All-
cause mortality rates were compared using the log-rank
test for the Kaplan-Meier curves. Factors contributing to
the all-cause mortality rates were examined using uni-
variate Cox proportional hazard regression analysis. In
addition to the serum adjusted calcium level, factors that
were significant in the univariate analysis served as ex-
planatory variables for the multivariate Cox proportional
hazard analysis using the stepwise method (i.e., serum
adjusted calcium, age, gender, BMI, SBP, DBP, CTR, his-
tory of CVD, use of calcium carbonate, hemoglobin,
serum albumin, eGFR, PTH, and CRP). In stratified ana-
lyses, all-cause mortality rates were compared by Cox









13.4 69.2 + 12.5 68.8 + 12.7 68.2 + 11.9 <0.001
5.3) 167 (31.5) 176 (33.7) 44 (40.0) 0.033
4.9 23.5 + 4.4 23.1 + 4.1 23.1 + 4.4 <0.001
28 152 + 25 150 + 26 148 + 28 0.129
7 77 + 15 76 + 15 74 + 15 <0.001
51.9) 275 (51.9) 275 (52.7) 60 (54.5) 0.007
6) 32 (6.0) 32 (6.1) 8 (7.3) 0.914
.6) 248 (46.8) 251 (48.1) 55 (50.0) <0.001
100-100) 100 (90-100) 100 (80-100) 100 (50-100) <0.001
60.6) 323 (60.9) 315 (60.3) 65 (59.1) 0.896
6.9) 197 (37.2) 182 (34.9) 25 (22.7) 0.025
4.1) 142 (26.8) 143 (27.4) 39 (35.5) 0.290
7.8) 194 (36.6) 165 (31.6) 36 (32.7) 0.254
5.7) 134 (25.3) 109 (20.9) 24 (21.8) 0.117
84.2) 476 (89.8) 449 (86.0) 83 (75.5) <0.001
1.5 9.5 + 1.5 9.4 + 1.6 9.4 + 1.4 0.002
0.58 3.29 + 0.54 3.10 + 0.62 2.89 + 0.67 <0.001
31.7 90.7 + 27.5 88.1 + 29.5 89.1 + 36.0 <0.001
1.95 5.44 + 1.92 5.77 + 2.28 6.30 + 3.48 <0.001
3.21 8.75 + 2.83 8.35 + 2.73 8.23 + 3.72 <0.001
0.29 8.51 + 0.28 9.34 + 0.27 10.45 + 0.59 <0.001
1.95 6.22 + 1.62 5.97 + 1.77 5.97 + 1.92 <0.001
144 260 + 164 259 + 202 265 + 155 0.441
274-518) 307 (208-429) 231 (147-360) 150 (71-230) <0.001
0.10-1.24) 0.20 (0.09-0.99) 0.30 (0.10-1.53) 0.62 (0.18-5.41) <0.001
195-1107) 636 (208-1295) 573 (132-1509) 465 (80-1161) 0.517
with 8.0 to <9.0 mg/dL, G4 with 9.0 to <10.0 mg/dL, and G5 with ≥10.0 mg/dL
cardiothoracic rate, CVD cardiovascular disease, ACEI angiotensin converting
vator, ESA erythropoiesis stimulating agent, BUN blood urea nitrogen, eGFR
in, NC nephrologist care
Fig. 1 Comparison of all-cause mortality among the five groups. Significant differences were observed between the five groups’ cumulative survival
rates (p = 0.005). G1 with a serum-adjusted calcium level <7.0 mg/dL, G2 with 7.0 to <8.0 mg/dL, G3 with 8.0 to <9.0 mg/dL, G4 with
9.0 to <10.0 mg/dL, and G5 with ≥10.0 mg/dL)
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of aortic or cardiac valve calcification between the five
groups of patient were performed using the chi-square
test. Comparisons of Barthel index score between the
five groups of patient were performed the analysis of
variance (ANOVA). P values less than 5% were consid-
ered statistically significant.
Results
Comparison of patient characteristics and baseline data
Table 1 shows the patient characteristics and baseline
data in the five groups. Significant differences between
the five groups were observed in age, gender, BMI, DBP,
prevalence of diabetes mellitus, history of CVD, BI, rate
of beta blockers use, rate of ESAs use, hemoglobin level,
serum albumin level, blood urea nitrogen (BUN) level,
eGFR, serum creatinine level, serum phosphorus level,
serum PTH level, and C-reactive protein (CRP) level.
Comparison of all-cause mortality
Figure 1 shows Kaplan-Meier curves for the cumulative
survival rates of the five groups. There were 268 deaths
during the follow-up period (G1, 9 cases; G2, 30 cases;
G3, 91 cases; G4, 110 cases; G5, 28 cases). Significant
differences were observed between the five groups’
cumulative survival rates (p = 0.005).
Factors affecting all-cause mortality
The results of univariate Cox proportional hazard regres-
sion analysis are presented in Table 2. The increase in
serum adjusted calcium levels was associated with the sur-
vival prognosis (every 1 mg/dL increase, hazard ratio
[HR] = 1.332, 95% confidence interval [CI] = 1.185 − 1.498,p < 0.001). In addition, high mortality was associated with
advanced age, male gender, low BMI, low blood pressure,
presence of cardiomegaly, history of CVD, no prior use of
renin angiotensin system (RAS) inhibitors, no prior use of
vitamin D receptor activator (VDRA), no prior use of
calcium carbonate, no prior ESA use, presence of anemia,
presence of hypoalbuminemia, high BUN level, high
eGFR, low serum creatinine level, low serum phosphorus
level, low PTH level, and high CRP level.
The results of multivariate Cox proportional hazard
analysis using the stepwise method are shown in Table 3.
Increasing serum adjusted calcium was associated with
survival prognosis (every 1 mg/dL increase, HR = 1.267,
95% CI = 1.092−1.470, p = 0.002). In addition, high
mortality was associated with advanced age, male gender,
low systolic blood pressure, history of CVD, and no
prior use of calcium carbonate.
Association of serum adjusted calcium levels with aortic
and cardiac valve calcification
The five groups based on serum adjusted calcium
levels at dialysis initiation were compared for aortic
and cardiac valve calcification. There were significant
differences in the incidence of either aortic or cardiac
valve calcification among the five groups (aortic calci-
fication p = 0.006, cardiac valve calcification p = 0.008).
The incidence of calcification was especially low for
G1 (Fig. 2).
Association between serum adjusted calcium levels and
the Barthel index
BI scores were compared among the five groups based
on serum adjusted calcium levels at dialysis initiation.
Table 2 Associations of variables with all-cause mortality according
to the univariate Cox proportional hazard regression analysis
Variables HR 95% CI p value
Serum adjusted calcium 1.332 1.185–1.498 <0.001
Age 1.057 1.045–1.070 <0.001
Female gender 0.685 0.521–0.901 0.007
BMI 0.912 0.882–0.943 <0.001
SBP (/10 mmHg) 0.922 0.892–0.953 <0.001
DBP (/10 mmHg) 0.837 0.789–0.888 <0.001
CTR 1.034 1.017–1.051 <0.001
Diabetes Mellitus 1.018 0.801–1.294 0.882
History of CVD 2.435 1.896–3.128 <0.001
Use of ACEIs or ARBs 0.732 0.576–0.931 0.011
Use of beta blockers 1.182 0.924–1.512 0.183
Use of VDRAs 0.708 0.529–0.949 0.021
Use of calcium carbonate 0.405 0.298–0.551 <0.001
Use of ESAs 0.657 0.482–0.896 0.008
Hemoglobin 0.883 0.818–0.953 0.001
Serum albumin 0.642 0.529–0.779 <0.001
BUN (/10 mg/dL) 1.041 1.004–1.080 0.032
eGFR 1.117 1.078–1.157 <0.001
Serum creatinine 0.868 0.826–0.912 <0.001
Serum phosphorus 0.927 0.865–0.993 0.032
PTH (/10 pg/mL) 0.994 0.988–0.999 0.034
CRP 1.036 1.017–1.056 <0.001
Duration of NC (/100 days) 0.989 0.978–1.001 0.066
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure,
CTR cardiothoracic rate, CVD cardiovascular disease, ACEI angiotensin converting
enzyme inhibitor, ARB angiotensin-1 receptor blocker, VDRA vitamin D
receptor activator, ESA erythropoiesis stimulating agent, BUN blood urea
nitrogen, eGFR estimated glomerular filtration rate, PTH parathyroid
hormone, CRP C reactive protein, NC nephrologist care
Table 3 Associations of variables with all-cause mortality according
to the multivariate Cox proportional hazard regression analysis
using the stepwise method
Variables HR 95% CI P value
Serum adjusted calcium 1.267 1.092-1.470 0.002
Age 1.045 1.030-1.060 <0.001
Female gender 0.656 0.471-0.912 0.012
SBP (/10 mmHg) 0.918 0.877-0.960 <0.001
History of CVD 1.656 1.229-2.231 <0.001
Use of calcium carbonate 0.580 0.409-0.822 0.002
Adjusted for serum adjusted calcium, age, gender, BMI, SBP, DBP, CTR, history
of CVD, use of calcium carbonate, hemoglobin, serum albumin, eGFR, PTH,
and CRP
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood
pressure, CTR cardiothoracic rate, CVD cardiovascular disease, eGFR estimated
glomerular filtration rate, PTH parathyroid hormone, CRP C reactive protein
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justed calcium levels (p < 0.001) (Fig. 3).
Stratified analysis
The association between serum adjusted calcium levels
and all-cause mortality was assessed with stratification
by age, gender, history of CVD, BI score, VDRA use, cal-
cium carbonate use, eGFR, and the PTH level. A signifi-
cant association between serum adjusted calcium levels
and all-cause mortality was observed in male patients
age 70 years and older, a history of CVD, the full score
of BI, VDRA use, no prior use of calcium carbonate, and
an eGFR ≥5 mL/min/1.73 m2 (Fig. 4).
Discussion
The present results revealed serum adjusted calcium
levels at dialysis initiation to be associated with all-cause
mortality after dialysis initiation. Moreover, multivariate
analysis identified a high serum adjusted calcium level as
an independent risk factor for poor survival prognosis.
Severe hypocalcemia is highly likely to occur during the
early period after dialysis initiation. On the other hand,
we found that high serum adjusted calcium levels were
associated with poor outcomes. In other words, patho-
logical conditions that inhibit the decrease in serum ad-
justed calcium levels might have been associated with
poor survival prognosis.
We considered that renal function at dialysis initiation
influenced serum adjusted calcium levels. As the glom-
erular filtration rate (GFR) decreases, serum phosphorus
and fibroblast growth factor 23 levels increase, followed
by a decrease in the serum activated vitamin D level. As
a consequence, the serum calcium level decreases. Thus,
if dialysis is initiated in patients with a high GFR, their
serum calcium may still be elevated. Regarding the asso-
ciation between renal function at dialysis initiation and
survival prognosis, there is reports describing the sur-
vival prognosis as being rather poor when dialysis is ini-
tiated in patients with a high eGFR [18, 19]. This is
considered to be attributable to many patients who
begin dialysis in the early stage being elderly, and also to
early initiation of dialysis being inevitable in some pa-
tients because of concurrent CVDs. The present study
also showed higher adjusted serum calcium levels at dia-
lysis initiation to be associated with higher eGFR, more
advanced age, and/or a greater likelihood of concurrent
CVDs. Because stratified analysis by eGFR revealed high
serum adjusted calcium levels to be associated with poor
survival prognosis, regardless of renal function level at
dialysis initiation, higher serum adjusted calcium levels
with respect to renal function might be a clinical issue.
Common causes of hypercalcemia include (1) hyperpara-
thyroidism, (2) malignancy, (3) chronic granulomatous
disease, (4) drugs (e.g., activated vitamin D preparations,
Fig. 2 Comparison of aortic and cardiac valve calcification among the five groups. Significant differences were observed between the five groups’
frequency of aortic and cardiac valve calcification (p = 0.006 and p = 0.008). G1 with a serum adjusted calcium level <7.0 mg/dL, G2 with 7.0 to
<8.0 mg/dL, G3 with 8.0 to <9.0 mg/dL, G4 with 9.0 to <10.0 mg/dL, and G5 with ≥10.0 mg/dL
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(6) adrenal insufficiency, (7) immobility, (8) total paren-
teral nutrition, and (9) milk-alkali syndrome [20]. We
considered that among above causes of hypercalcemia,
drugs or immobility led to increase in serum adjusted
calcium level inconsistent with renal function. Because
many reports have recently indicated that the use of
calcium-containing phosphate binders in patients with
dialysis worsens survival prognosis [21–23], we addition-
ally examined drugs affecting serum calcium levels. The
rate of using thiazide diuretics, VDRA, or calcium-
containing phosphate binders did not differ significantly
among the groups. After the patients were stratified
based on the use of VDRA or calcium-containing phos-
phate binders, the effects of these drugs on survivalFig. 3 Comparison of Barthel index score among the five groups. Significan
score (p < 0.001). G1 with a serum adjusted calcium level <7.0 mg/dL, G2 w
<10.0 mg/dL, and G5 with ≥10.0 mg/dL. ANOVA, analysis of varianceprognosis were assessed. Regardless of the use of these
drugs, high serum adjusted calcium levels were generally
associated with poor survival prognosis. Thus, when
these serum calcium-elevating drugs are used, it would
apparently be important to maintain the serum adjusted
calcium concentration at “a level commensurate with
renal function”. The use of calcium carbonate was unex-
pectedly associated with better prognosis in the present
study. Comparison of serum adjusted calcium and phos-
phorus levels between use and no use of calcium
carbonate groups showed no significant differences
(Additional file 1: Figure S1). In other word, patients
who took more amount of phosphorus intake were likely
administered calcium carbonate. We suspected that
those of patients probably took sufficient dietary proteint differences were observed between the five groups’ Barthel index
ith 7.0 to <8.0 mg/dL, G3 with 8.0 to <9.0 mg/dL, G4 with 9.0 to
Fig. 4 Stratified risk factors affecting all-cause mortality associated with serum adjusted calcium. Adjusted for serum adjusted calcium, age, gender, BMI,
SBP, DBP, CTR, history of CVD, use of ACEIs or ARBs, use of VDRAs, use of calcium carbonate, use of ESAs, hemoglobin, serum albumin, BUN, eGFR, serum
phosphorus, PTH, and CRP. VDRA; vitamin D receptor activator, CC; calcium carbonate, eGFR; estimated glomerular filtration rate, PTH; parathyroid hormone
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led to better prognosis during the relatively short term
follow up period.
In the present study, patients with a high serum
adjusted calcium level at dialysis initiation included
many elderly as well as those with a low BI score, which
reflects ADL. Thus, increased serum calcium levels due
to immobility, one of the above-described causes of
hypercalcemia, might have contributed to our results.
Immobility promotes bone resorption via mobilization
of calcium from bone, which in turn causes hypercalce-
mia [24, 25]. Consequently, PTH levels are suppressed.
In the present study, PTH levels decreased as serum
adjusted calcium levels rose. This result appears to be
consistent with the known effects of immobility.
Elevated serum calcium is known to be a factor pro-
moting vascular calcification [26]. Moreover, vascular
calcification is an important pathological condition that
affects survival prognosis [27]. The results of the present
study revealed the prevalence of aortic and cardiac valve
calcification to be higher in patients with higher serum-
adjusted calcium levels. This suggests that the poor
survival prognosis in patients with higher serum ad-
justed calcium levels might be attributable to advanced
organ dysfunction due to vascular calcification. However,
it is also possible that such ectopic calcification is
strongly associated with age-related factors.
The present study has the following limitations. First,
because of the observational study design, there were
differences in patient characteristics and baseline dataamong the groups, although the data were adjusted for
several of these factors. We could not exclude the bias
because several factors including age, gender, BMI,
diabetes, and history of CVD were strongly associated
mortality in general. Second, there was difference in the
number of patients among the five groups. Hence, we
conducted comparison of all-cause mortality between
five groups classified by quintile of serum adjusted
calcium. We considered that the bias was at minimum be-
cause the results were similar (Additional file 2: Figure S2).
Third, the extent to which low BI scores reflect bone
resorption due to immobility is unknown. The subjects of
the present study were limited to patients who could be
discharged to home or transferred to another facility after
dialysis initiation. Thus, there were only a few patients with
very low ADL who were bedridden 24 h a day. In this
situation, it is not certain whether the physical activity levels
of the patients can be regarded as “immobility.” Fourth,
neither vascular nor cardiac valve calcification was assessed
quantitatively. As the severity calcification was not consid-
ered, i.e., cases with mild to severe calcifications were
handled equally in performing the analyses, this study lacks
sufficient objectivity to identify calcification as a cause of
poor prognosis.Conclusions
Serum-adjusted calcium levels at dialysis initiation were
demonstrated to be associated with all-cause mortality
after dialysis initiation.
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Additional file 1: Figure S1. Comparison of serum adjusted calcium
and phosphorus level between use and no use of calcium carbonate
groups. No significant differences were observed between the two
groups’ serum mineral levels (p = 0.071 and p = 0.634) by t test. (TIF 40 kb)
Additional file 2: Figure S2. Comparison of all-cause mortality among
the five groups classified by quintile of serum adjusted calcium. Significant
differences were observed between the five groups’ cumulative survival
rates (p < 0.001). Q1 with the lowest serum adjusted calcium level, Q5 with
the highest serum adjusted calcium level. (TIF 42 kb)
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